Galecto Inc
Research Galecto Inc (GLTO) on Bullrun: market cap USD 1.16B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGLTO
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.16B
- Financial periodQ3 2025
- RevenueUSD 0
- Net income-USD 3.13M
- Free cash flow-USD 2.62M
Valuation Snapshot
latest market cap is USD 1.16B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 0 | -USD 21.44M | -USD 18.62M | n/a | -18.53 | USD 14.18M | USD 73.00K | USD 15.83M |
| FY2023 | USD 0 | -USD 38.35M | -USD 36.91M | n/a | -36.08 | USD 21.47M | USD 249.00K | USD 32.33M |
| FY2022 | USD 0 | -USD 61.62M | -USD 43.13M | n/a | -60.75 | USD 32.79M | USD 804.00K | USD 61.75M |
| FY2021 | USD 0 | -USD 51.75M | -USD 52.53M | n/a | -51.25 | USD 62.56M | USD 847.00K | USD 117.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-03-13 | USD 1.16B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 36.75M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.12M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 29.42M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 76.55M | n/a | n/a | n/a |
About Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Galecto Inc's market cap?
Galecto Inc's market capitalization is USD 1.16B.
What does Galecto Inc do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.